# A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

> **NCT03557619** · PHASE1 · RECRUITING · sponsor: **AbbVie** · enrollment: 12 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** ethinyl estradiol/levonorgestrel

## Key facts

- **NCT ID:** NCT03557619
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-07-30
- **Primary completion:** 2026-03-21
- **Final completion:** 2026-03-21
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03557619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03557619, "A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03557619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*